• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ATH
Click for more information
0.00% 0.5¢

ALTERITY THERAPEUTICS LIMITED - Charts / Financials

Market Cap $26.22M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company.... Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits
refresh Created with Sketch. REFRESH
Last update - 10.00am 04/06/2024 (20 minute delay) ?
Day
Open 0.0¢   Day High 0.0¢   Day Low 0.0¢
Daily Volume 0
Bids   Sellers
Number Price Volume   Number Price Volume
1 0.5¢ 2000000   4 0.4¢ 1799999

Directors & Senior Management

Dr. David A. Stamler Chief Executive Officer
Mr. Phillip D. Hains Chief Financial Officer, Company Secretary
Mr. Geoffrey Paul Kempler Non-Executive Chairman of the Board
Mr. Lawrence B. Gozlan Non-Executive Director
Mr. Peter Ashley Marks Non-Executive Independent Director
Mr. Brian Derek Meltzer Non-Executive Independent Director

Data source: Refinitiv

(20min delay)
Last
0.5¢ 		Change
0.000(0.00%) 		Mkt cap ! $26.22M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
1 2000000 0.5¢
 

Sellers (Offers)

Price($) Vol. No.
0.4¢ 1799999 4
View Market Depth
Last trade - 09.52am 04/06/2024 (20 minute delay) ?

Top Stories

Infini boosts WA uranium holdings with Bellah Bore East acquisition

Infini Resources Ltd has increased its uranium project portfolio in Western Australia with the acquisition of Bellah Bore East
Immutep targets $100m for lung cancer drug trial tests Immutep has launched a capital raise aiming to boost its war chest by $100 million to progress late stage trials for lung cancer sufferers.
Drilling doubles gold-copper mineralisation zone at GEO-01 for Antipa Antipa Minerals Ltd has announced it has doubled the mineralisation zone of its GEO-01 target in Western Australia through drilling.
Daily ASX Market Open: Commodity prices to weigh | June 4, 2024 The pricing of key commodities will matter this morning – as both iron ore and oil were tipped to fall on overseas markets - and that’s set to weigh on the ASX200. Futures suggests the index will tip just slightly into the red (0.13%).
Kincora secures untested porphyry project Wongarbon in prime territory Kincora Copper Ltd has acquired the Wongarbon project in New South Wales which it believes hosts a notable porphyry complex.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.